Quiz #3 Material Flashcards
1
Q
Hemostasis: four major events occur following a wound
A
- VPCF
-
Vascular Constriction:
- Limits the flow of blood to the injury
-
Platelet aggregation:
- Blood platelets clump when binding to collagen that becomes exposed following rupture. Blood platelets become activated and aggregate at the site of injury
-
Clot formation:
- To inure stability of the initially loose platelet plug, a fibrin mesh (aka clot) forms and entraps the plug
-
Fibrinolysis:
- The clot must be dissolved in order for normal blood flow to resume following tissue repair. The dissolution of the clot occurs through the action of plasmin
2
Q
Platelets
A
- Platelets are NOT cells but really just a type of vesicle that pinches off of the megakaryocyte.
- No nucleus
- Hemopoetic stem cell→Promegakaryocyte→Megakaryocyte→Platelet
3
Q
Major Drugs Acting on Platelets:
- ADP antagonists
- PDE Inhibitor
- Platelet surface bind
- COX inhibitor
- (Multiple Mechanisms)
A
- ADP antagonists
- Clopidogrel (Plavix)
- Ticlopidine (Ticlid)
- Prasugrel (Ticagrelor)
- PDE Inhibitor
- Dipyridamole (Aggrenox)
- Platelet surface bind
- Abciximab (ReoPro)
- Tirofiban (Aggrastat)
- Eptifibatide (Integrelin)
- COX inhibitor
- Aspirin
- (Multiple Mechanisms)
- Thrombin
4
Q
Three Steps of Clot Formation
A
- Activation
- Activation/Adhesion of platelets
- Release
- Release of factors to drive the activation and adhesion of platelets (ADP, thromboxane A2)
- Recruitment
- Recruitment of more platelets, aggregation and formation of a clot
5
Q
Important Concept of Platelet Aggregation Mechanism
A
- Works on a feed-forward mechanism
- Is turned off by excretions from the endothelium
- EDRF, PGI2, tPA, and heparin
6
Q
Thrombin
A
- Factor IIa
- Cleaves N-terminus of PAR-1
- Leaves behind a ‘tethered ligand’ that can provide continuous activity of the receptor until receptor recycling
- Irreversible (actually slowly reversible)
7
Q
Molecular Basis of Platelet Aggregation and Activation
A
- Collagen/damaged endothelium bind Von Willebrand Factor which in turn has high affinity for GP1b/Gp IIb
- Gp Ia: platelet receptor for collagen
- Gp Ib: platelet receptor for VWF
- Gp IIb-IIIa: integrin that binds fibrin
- Antagonists to GpIIb/IIIa prevent binding to fibrin
- Abciximab (Reopro): coronoary artery procedures to prevent platelet sticking
- Tirofiban (RGD)
- Eptifibatide (Integrilin, C-term of fibrinogen)
8
Q
Synthesis and Effects of Arachadonic Acid Metabolites
A
-
COX Enzymes metabolize arachadonic acid, leading to the production of thromboxanes and prostacyclin
- Thromboxanes: made in platelets and lead to increased platelet aggregration
- Prostacylin: made in endothelial tissue and lead to decreased platelet aggregation
- opposing factors
9
Q
Action of Aspirin
A
-
Irreversibly inhibits COX to inhibit both:
- Inhibits thrombaxane synthesis: decrease in platelet aggregation
- Can’t be produced by COX enzmes until platelets are fully recycled
- Inhibits prostacyclin synthesis
- Can be recovered because endothelial cells have nuclei
- Inhibits thrombaxane synthesis: decrease in platelet aggregation
- Aspirin + PGHS2→Salicylic acid + acetylated PGHS2
- Use low dose:
- Platelet COX1 has highest affinity for aspirin
- Aspirin doesn’t inhibit endothelium COX1
10
Q
Ibuprofen and other NSAIDS
A
- Other NSAIDs don’t work for clotting because they are reversible
11
Q
Ticlid and Plavix
A
- Thienopyridines
- ADP receptor antagonists
- Prevent recuring DVT, strokes and intermittent claudication
- Plavix (clopidogrel)
- Requires activation by CYP2C19
- Low dose ASA + Plavix not more effective than ASA alone
- Thrombocytic thrombocytopenia
- Ticlid (ticlopidine)
- Safety? bleeds and hemorraging
- THM: Covalent/Irreversible
12
Q
newer ADP receptor antagonists
A
- Prasugrel (Effient)
- Requires enzymatic activation
- Noncompetitive antagonist at the P2Y12 purinergic receptor
- Ticagrelor (Brilinta)
- Reversible allosteric agonist
- Better safety and efficacy when used in combo with ASA?
13
Q
Dipyridamole
A
- Dipyridamole (Persantin)
- Cilostazol, PDE3 inihibitor, approved for intermittent claudication
- Aggrenox
- Dipyridamole with tartaric acid to solubilize
- Sustained release pellets with ASA
14
Q
Factors on platelet surface involed in clot formation
A
- GpIa: receptor for collagen
- GpIb: receptor of VWF
- GpIIb-GpIIIa: integrin that binds fibrin
15
Q
ADP Receptor Antagonists: MOA and Example
A
- Block the ADP receptor from being activated by ADP→block platelet adhesion
- Plavix (clopidegrel) falls into this category
16
Q
Clotting Cascade: Key Players
A
- Xa: converts prothrombin→thrombin
- IIa: thrombin; converts fibrinogen→fibrin
- XIIIa: transglutaminase enzyme that converts soluble fibrin to insoluable fibrin, the final step of the clotting cascade